Sign Up Today and Learn More About Cartography Biosciences Stock
Invest in or calculate the value of your shares in Cartography Biosciences or other pre-IPO companies through EquityZen's platform.
Cartography Biosciences Stock (CABO)
Cartography is shaping a world in which cancer immunotherapies are designed around and directed toward the safest, most effective targets.
About Cartography Biosciences Stock
Founded
2020
Headquarters
Foster City, CA, US
Industries
Artificial Intelligence, Software, Data and Analytics
Cartography Biosciences Press Mentions
Stay in the know about the latest news on Cartography Biosciences
Cartography Biosciences: Strategic Investment From Samsung Ventures To Advance Oncology Pipeline
pulse2 • May 08, 2026
Cartography Biosciences Receives Investment From Samsung Ventures
finsmes • May 07, 2026
Cartography Biosciences Announces Strategic Investment From Samsung Ventures to Advance Oncology Pipeline
pharmiweb • May 07, 2026
Cartography Biosciences, Samsung Life Science Fund, ParcelBio
biotech-finances • May 07, 2026
Cartography Biosciences Announces Strategic Investment From Samsung Ventures to Advance Oncology Pipeline
biospace • May 07, 2026
Cartography Biosciences Management
Leadership team at Cartography Biosciences
CEO, Co-Founder
Kevin Parker
Founder
Ansuman Satpathy
Join now and verify your accreditation status to gain access to:
- Cartography Biosciences Current Valuation
- Cartography Biosciences Stock Price
- Cartography Biosciences Management
- Available deals in Cartography Biosciences and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Cartography Biosciences Cap Table and Funding History by Share Class and Liquidity Preferences
- Cartography Biosciences Revenue and Financials
- Cartography Biosciences Highlights
- Cartography Biosciences Business Model
- Cartography Biosciences Risk Factors
- Cartography Biosciences Research Report from SACRA Research
Trading Cartography Biosciences Stock
How to invest in Cartography Biosciences stock?
Accredited investors can buy pre-IPO stock in companies like Cartography Biosciences through EquityZen funds. These investments are made available by existing Cartography Biosciences shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Cartography Biosciences stock?
Shareholders can sell their Cartography Biosciences stock through EquityZen's private company marketplace. EquityZen's network includes over 470K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 54K private placements completed across 500+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
